ClinicalTrials.Veeva

Menu
W

Well Pharma Medical Research, Corp | Miami, FL

Research site
(Unclaimed)

Site insights

Top conditions

Top treatments

Ruxolitinib
MK-7264
Atogepant
Gefapixant
Fluticasone
Diclofenac
Metformin
Montelukast
BMS-986165
SEL-212

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

13 of 65 total trials

A 104-Week Study of Ritlecitinib Oral Capsules in Adults With Nonsegmental Vitiligo (Active and Stable) Tranquillo 2

The purpose of this study is to learn about the safety and effects of the study medicine ritlecitinib for the possible treatment of nonsegmental viti...

Enrolling
Stable Nonsegmental Vitiligo
Active Nonsegmental Vitiligo
Drug: Ritlecitinib
Drug: Placebo

This is a randomized, double-blind, placebo-controlled, parallel-arm, Phase 3 study of BLU-5937 in participants with Refractory Chronic Cough (RCC).

Enrolling
Refractory Chronic Cough
Drug: BLU-5937
Drug: Placebo

This is an interventional, randomized, parallel group, treatment, Phase IIb, double blind, 4-arm study to assess the effect of pegylated-recombinant-...

Enrolling
Moderate to Severe Atopic Dermatitis
Drug: Rezpegaldesleukin
Drug: Placebo

The primary purpose of this study is to assess the effect of verekitug (UPB-101) on the endoscopically determined size and extend of nasal polyps in...

Enrolling
Chronic Rhinosinusitis With Nasal Polyps
Drug: Placebo
Drug: Verekitug (UPB-101)

A double-blind, randomized, placebo-controlled, parallel-group, multi-site, clinical trial to confirm the efficacy and safety of single injection of...

Active, not recruiting
Osteoarthritis
Drug: RTX-GRT7039
Drug: Placebo

This is a phase IIa, randomized, double-blind, placebo-controlled, multi-center proof-of-concept (POC) study in subjects with moderate to severe Atop...

Enrolling
Atopic Dermatitis
Drug: Placebo
Drug: ADX-914
Locations recently updated

This is designed to assess the long-term safety and efficacy of lebrikizumab for moderate-to-severe atopic dermatitis. It will last up to 33 months.

Active, not recruiting
Atopic Dermatitis
Biological: Lebrikizumab

The main purpose of this study is to characterize the long-term safety and efficacy of the drug Deucravacitinib (BMS-986165) in patients who have bee...

Active, not recruiting
Psoriasis
Drug: BMS-986165

The goal of this clinical study is to determine if a single injection of 1 or more dose levels of adeno-associated virus (AAV) gene therapy (GNSC-001...

Active, not recruiting
Knee Osteoarthritis
Osteo Arthritis Knee
Drug: transient immune-modulation
Drug: Placebo
Locations recently updated

The purpose of this trial is to investigate the efficacy and safety of dapansutrile (OLT1177®) tablets in subjects with an acute gout flare.

Enrolling
Gouty Arthritis
Gout Attack
Other: Placebo Tablet
Drug: Dapansutrile

A migraine is a moderate to severe headache typically on one side of the head. A migraine attack is a headache that may be accompanied by throbbing,...

Enrolling
Migraine
Drug: Ubrogepant
Drug: Placebo for Ubrogepant

The purpose of this study is to evaluate the efficacy and safety of ruxolitinib cream in adult participants with diagnosis of chronic hand eczema (CH...

Active, not recruiting
Hand Eczema
Drug: Ruxolitinib cream
Drug: Vehicle

The purpose of this study is to measure the change in pain and function with subcutaneous injections of pentosan polysulfate sodium (PPS) compared wi...

Active, not recruiting
Osteoarthritis, Knee
Drug: Pentosan Polysulfate Sodium once weekly
Drug: Pentosan Polysulfate Sodium twice weekly

Trial sponsors

S
Allergan logo
Incyte logo
Merck Sharp & Dohme (MSD) logo
I
Lilly logo
AbbVie logo
Bristol-Myers Squibb (BMS) logo
C
Ironwood Pharmaceuticals logo

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems